ITGA4 Gene Methylation Status in Chronic Lymphocytic Leukemia
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
|ClinicalTrials.gov Identifier: NCT05371392
Recruitment Status : Not yet recruiting
First Posted : May 12, 2022
Last Update Posted : May 12, 2022
Chronic lymphocytic leukemia (CLL) is a clonal lymphoproliferative disorder that is characterized by heterogeneous presentation at the clinical and molecular levels. ITGA4 protein has been found to be deregulated in CLL with adverse clinical outcome. ITGA4 gene (CD49d) encodes a member of the integrin alpha chain family of proteins and is considered a negative prognosticator in CLL with aggressive course and short time to treatment.
The aim of the study:
is to investigate ITGA4 gene expression pattern and to explore its methylation heterogeneity in CLL.
|Condition or disease
|Chronic Lymphocytic Leukemia
|Study Type :
|Estimated Enrollment :
|ITGA4 Gene Methylation Status in Chronic Lymphocytic Leukemia
|Estimated Study Start Date :
|July 1, 2022
|Estimated Primary Completion Date :
|August 1, 2023
|Estimated Study Completion Date :
|October 1, 2023
- ITGA4 gene expression pattern and its methylation heterogeneity in chronic lymphocytic leukemia [ Time Frame: 1 year following the startpoint of the study ]Detection of ITGA4 gene expression and ITGA4 gene methylation in blood samples in patients with chronic lymphocytic leukemia, Briefly, total RNA and genomic DNA extraction from fresh peripheral blood samples by Real-time -RT-polymerase chain reaction system (RT-PCR) will be carried out. Rate of ITGA4 gene expression and its methylation will be recorded.